Prostate Cancer

Prostate cancer

The most common cancer in men

More than 160,000 men are diagnosed annually with  prostate cancer in the US. The nature of the tumors – and the course of treatment – can vary widely. Some prostate cancers grow and spread quickly requiring aggressive treatment, while others grow and spread slowly. 

A clear understanding of the cancer, helps to ensure that you are on the right treatment path.


The prostate-specific antigen (PSA) test is currently used to screen men for prostate cancer. However, there are limitations to the information this test provides regarding how aggressive the cancer is. As a result, there is significant overdiagnosis of indolent non-high grade cancer and consequent overtreatment.

The facts about

1 %

Up to 80% of prostate biopsies are potentially unnecessary – negative or indolent 

cancer on biopsy 1 

1 %

Following a prostate biopsy, up to

15% of men suffer complications 2


1 %

Within 30 days of prostate biopsy

up to 5% of men are hospitalized 3 


1.Thompson et al. Journal of the National Cancer Institute 2006. 2. Loeb et al. European Urology 2013. 3. Liss et al. The Journal of Urology 2017.

How can EPI help?

The EPI test helps you and your doctor in the shared decision making process.

With a binary cut-point risk stratification EPI can help you and your doctor to make a more informed prostate biopsy decision. 

This test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number – 22D2093470

Exosome Diagnostics and ExoDx, are registered and unregistered trademarks of Exosome Diagnostics, Inc.